Forget biosimilars. Peter Bach and Mark Trusheim believe price controls are the better way to rein in biologics prices
The proverbial social contract that drugmakers often cite to defend prescription drug prices hinges on the image of a patent cliff: After a period of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
